Drug Profile
Metreleptin - Amryt Pharma
Alternative Names: Human recombinant methionyl leptin; Methionyl human leptin; Myalept; MYALEPTA; r-metHuLeptin; Recombinant methionyl human leptinLatest Information Update: 07 Feb 2024
Price :
$50
*
At a glance
- Originator Amgen
- Developer Amgen; Amryt Pharma; Beth Israel Deaconess Medical Center; Shionogi; University of Texas Southwestern Medical Center
- Class Adipokines; Antihyperglycaemics; Obesity therapies; Recombinant proteins
- Mechanism of Action Leptin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Lipodystrophy
- Phase II Amenorrhoea
- Phase I Lipomatosis
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 05 Feb 2024 Registered for Lipodystrophy (In adults, In adolescents, In children) in Canada (SC)
- 12 Apr 2023 Amryt Pharma has been acquired by Chiesi Farmaceutici
- 10 Feb 2023 Phase-I clinical trials in Lipomatosis (In neonates, In infants, In children, In adults, In adolescents) in USA (SC) (NCT05351164)